Publicaciones en las que colabora con Eulogio Conde García (20)

2016

  1. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

    Bone Marrow Transplantation, Vol. 51, Núm. 7, pp. 961-966

2011

  1. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

    Blood, Vol. 118, Núm. 3, pp. 529-534

2008

  1. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

    European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235

  2. Primary mediastinal large cell lymphoma (PMBL): Frontline treatment with autologous stem celltransplantation (ASCT). The GEL-TAMO experience

    Hematological Oncology, Vol. 26, Núm. 3, pp. 171-178

2007

  1. Tho adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

    Haematologica, Vol. 92, Núm. 8, pp. 1067-1074

2005

  1. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

    Annals of Oncology, Vol. 16, Núm. 4, pp. 625-633

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

2003

  1. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience

    Annals of Oncology, Vol. 14, Núm. 12, pp. 1768-1775

  2. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group

    Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151

  3. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial

    British Journal of Haematology, Vol. 120, Núm. 2, pp. 296-303

2002

  1. Myeloablative treatments for multiple myeloma: Update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma

    Leukemia and Lymphoma, Vol. 43, Núm. 1, pp. 67-74

2001

  1. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens

    Bone Marrow Transplantation, Vol. 27, Núm. 4, pp. 405-412

  2. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    Journal of Clinical Oncology, Vol. 19, Núm. 5, pp. 1395-1404

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

  3. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

    British Journal of Haematology, Vol. 109, Núm. 2, pp. 438-446

1997

  1. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL-TAMO cooperative group

    Bone Marrow Transplantation, Vol. 20, Núm. 4, pp. 283-288

  2. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 34-41

  3. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica. Registro Español de Trasplante en Mieloma.

    Sangre, Vol. 42 Suppl 1, pp. 38-41

1994

  1. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the spanish cooperative group GEL/TAMO

    Bone Marrow Transplantation, Vol. 14, Núm. 2, pp. 279-286